Everything below concerns Ac-SDKP. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
=== X-Ray Scattering === In 1953, Kaesberg and a few colleagues used x-ray scattering to determine the size and hydration of three different viruses: the southern bean mosaic virus, the tomato bushy stunt virus, and the tobacco necrosis virus. All three of the viruses had a sphere-like shape and internal hydration. They differed, however, in their diameters, with the tobacco necrosis virus having a diameter of 280 angstroms, the southern bean virus having a diameter of 286 angstroms, and the tomato bushy stunt virus having the largest diameter of them all: 309 angstroms. In 1954, Kaesberg and Paul Schmidt utilized small-angle X-ray scattering to measure the size of the yellow turnip mosaic virus and its associated protein. They found that both particles were almost spherical and the same size. They found that while the virus had a relatively constant electron density, the protein was a water-filled shell. In 1963, Margaret Wright and Paul Kaesberg used x-ray scattering to learn more about the inside of the bromegrass mosaic virus. They discovered that the virus had a 260 angstroms diameter and an inner region with an 80-angstrom diameter. Negatively stained bromegrass viruses had a slightly larger internal diameter, about 90 angstroms. They saw that the internal region was almost wholly empty and that the RNA and protein within the virus had almost equal electron densities. However, they noticed something different in the positively stained viruses. These viruses have nucleic acids compacted into a shell formation enveloped by proteins.
=== Pathways === Opinions differ about optimal screening and diagnostic measures, partly due to differences in population risks, cost-effectiveness considerations, and lack of an evidence base to support large national screening programs. The most elaborate regimen entails a random blood glucose test during a booking visit, a screening glucose challenge test around 24–28 weeks' gestation, followed by an OGTT if the tests are outside normal limits. If there is a high suspicion, a woman may be tested earlier. In the United States, most obstetricians prefer universal screening with a screening glucose challenge test. In the United Kingdom, obstetric units often rely on risk factors and a random blood glucose test. The American Diabetes Association and the Society of Obstetricians and Gynaecologists of Canada recommend routine screening unless the woman is low risk (this means the woman must be younger than 25 years and have a body mass index less than 27, with no personal, ethnic or family risk factors) The Canadian Diabetes Association and the American College of Obstetricians and Gynecologists recommend universal screening. The U.S. Preventive Services Task Force found there is insufficient evidence to recommend for or against routine screening, and a 2017 a Cochrane review found that there is not evidence to determine which screening method is best for women and their babies.
The CCT then causes actin's sequential folding by forming bonds with its subunits rather than simply enclosing it in its cavity. This is why it possesses specific recognition areas in its apical β-domain. The first stage in the folding consists of the recognition of residues 245–249. Next, other determinants establish contact. Both actin and tubulin bind to CCT in open conformations in the absence of ATP. In actin's case, two subunits are bound during each conformational change, whereas for tubulin binding takes place with four subunits. Actin has specific binding sequences, which interact with the δ and β-CCT subunits or with δ-CCT and ε-CCT. After AMP-PNP is bound to CCT the substrates move within the chaperonin's cavity. It also seems that in the case of actin, the CAP protein is required as a possible cofactor in actin's final folding states. The exact manner by which this process is regulated is still not fully understood, but it is known that the protein PhLP3 (a protein similar to phosducin) inhibits its activity through the formation of a tertiary complex.
The administration has left financing for eradication projects in the Andes largely unchanged, despite debate over whether such efforts can sharply restrict the supply of cocaine or significantly increase the price in the United States in the long run. American anti-narcotics aid for Peru stands at $71.7 million this year, slightly higher than last year's $70.7 million. American anti-narcotics officials operate from a newly expanded Peruvian police base in Tingo María, overseeing Peruvian teams that fan out to nearby valleys to cut down coca bushes by hand.
Sources: en.wikipedia.org
=== Synthesis === The procedure involving organometallic addition of methyl lithium to estrone works in very high yield but not the Grignard reagent. The patent stated that methylestradiol has the advantage that it is orally much more active than estradiol.
== Frequency == BED is the most common eating disorder, with 47% of people with eating disorders having BED, 3% of them have anorexia nervosa, and 12% of them have bulimia nervosa. Over 57% of people with BED are female and it often begins in the late teens or early 20s.
The sample may be introduced into the column at any time during the column equilibration step or after equilibration has been accomplished. After the volume of eluant surpasses the volume of the mobile phase in the column, the sample components will begin to elute. Compounds with a partition coefficient of unity will elute when one column volume of mobile phase has passed through the column since the time of injection. The compound can then be introduced to another stationary phase to help increase the resolution of results. The flow is stopped after the target compound(s) are eluted or the column is extruded by pumping the stationary phase through the column. An example of a major application of countercurrent chromatography is to take an extremely complex matrix such as a plant extract, perform the countercurrent chromatography separation with a carefully selected solvent system, and extrude the column to recover all of the sample. The original complex matrix will have been fractionated into discrete narrow polarity bands, which may then be assayed for chemical composition or bioactivity. Performing one or more countercurrent chromatography separations in conjunction with other chromatographic and non chromatographic techniques has the potential for rapid advances in compositional recognition of extremely complex matrices.
For this reason, collective bacteria and other microorganisms in a host are often called "flora". The term "bacteria" was traditionally applied to all microscopic, single-cell prokaryotes. However, molecular systematics showed prokaryotic life to consist of two separate domains, originally called Eubacteria and Archaebacteria, but now called Bacteria and Archaea that evolved independently from an ancient common ancestor. Archaea and eukaryotes are more closely related to each other than either group is to bacteria. This relationship forms the basis of the current widely-used three-domain system, which recognises Bacteria, Archaea, and Eukarya as the three primary domains of life. However, due to the relatively recent introduction of molecular systematics and a rapid increase in the number of genome sequences that are available, bacterial classification remains a changing and expanding field. For example, Cavalier-Smith argued that the Archaea and Eukaryotes evolved from Gram-positive bacteria. The identification of bacteria in the laboratory is particularly relevant in medicine, where the correct treatment is determined by the bacterial species causing an infection. Consequently, the need to identify human pathogens was a major impetus for the development of techniques to identify bacteria. Once a pathogenic organism has been isolated, it can be further characterised by its morphology, growth patterns (such as aerobic or anaerobic growth), patterns of hemolysis, and staining.
The ability of the medium to swell in liquid is based on the cross-linking of these substances, the pH and the ion concentrations of the buffers used. Incorporation of high temperature and pressure allows a significant increase in the efficiency of ion chromatography, along with a decrease in time. Temperature has an influence of selectivity due to its effects on retention properties. The retention factor (k = (tRg − tMg)/(tMg − text)) increases with temperature for small ions, and the opposite trend is observed for larger ions. Despite ion selectivity in different mediums, further research is being done to perform ion exchange chromatography through the range of 40–175 °C. An appropriate solvent can be chosen based on observations of how column particles behave in a solvent. Using an optical microscope, one can easily distinguish a desirable dispersed state of slurry from aggregated particles.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.